[go: up one dir, main page]

AR108263A1 - Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo - Google Patents

Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo

Info

Publication number
AR108263A1
AR108263A1 ARP170101111A ARP170101111A AR108263A1 AR 108263 A1 AR108263 A1 AR 108263A1 AR P170101111 A ARP170101111 A AR P170101111A AR P170101111 A ARP170101111 A AR P170101111A AR 108263 A1 AR108263 A1 AR 108263A1
Authority
AR
Argentina
Prior art keywords
general formula
compound
hydroxialquil
triazol
phenyl
Prior art date
Application number
ARP170101111A
Other languages
English (en)
Inventor
Kersten Matthias Gericke
Frank Sormeier
Hans Militzer
- Rubenbauer Philipp Christian
Heiko Schirmer
Chantal Forstner
Thomas Neubauer
Marie-Pierre Collin
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of AR108263A1 publication Critical patent/AR108263A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Un procedimiento que comprende los pasos [C] y [D], en donde [C] es un compuesto de fórmula general (2), en donde R² es C₁₋₄-alquilo, preferentemente es metilo, se hace reaccionar sucesivamente en un primer paso [C-1] en presencia de una base cloruro de ácido de la fórmula general (3) en donde PG es un grupo protector, preferentemente es acetilo, y el producto intermedio resultante se hace reaccionar en un paso subsiguiente [C-2] en presencia de una base con un compuesto de fenilhidrazina de la fórmula general (4), en donde R¹A y R¹B se seleccionan independientemente del grupo que consiste en hidrógeno, flúor, cloro, metilo, monofluorometilo, difluorometilo, trifluorometilo, etilo, metoxi, difluorometoxi y trifluorometoxi, a un compuesto de 1,2,4-triazolilo de la fórmula general (5), en donde PG, R¹A y R¹B son como se ha definido anteriormente, y se hace reaccionar en un paso subsiguiente [D] por escisión del grupo protector PG a un compuesto de la fórmula general (1) en donde R¹A y R¹B son como se ha definido anteriormente.
ARP170101111A 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo AR108263A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16168163 2016-05-03

Publications (1)

Publication Number Publication Date
AR108263A1 true AR108263A1 (es) 2018-08-01

Family

ID=55910849

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP170101111A AR108263A1 (es) 2016-05-03 2017-05-02 Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
ARP170101113A AR108265A1 (es) 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP170101113A AR108265A1 (es) 2016-05-03 2017-05-02 Derivados de feniltriazol sustituidos con amida y usos de estos

Country Status (6)

Country Link
US (1) US10815205B2 (es)
EP (1) EP3452470B1 (es)
AR (2) AR108263A1 (es)
TW (1) TW201806943A (es)
UY (1) UY37221A (es)
WO (1) WO2017191107A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3700896A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Amine substituted triazole derivatives and uses thereof
WO2019081303A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081291A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
WO2019081307A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF
BR112020007983A2 (pt) 2017-10-24 2020-10-27 Bayer Aktiengesellschaft pró-fármacos de derivados de triazol substituído e usos dos mesmos
EP3700899A1 (en) 2017-10-24 2020-09-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
CA3084411A1 (en) 2017-10-24 2019-05-02 Bayer Pharma Aktiengesellschaft Substituted triazole derivatives and uses thereof
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
KR20220008956A (ko) 2020-07-14 2022-01-24 삼성전자주식회사 반도체 소자
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
AU2004309164B2 (en) 2003-12-22 2007-11-15 Pfizer Inc. Triazole derivatives as vasopressin antagonists
CA2563963A1 (en) 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
PE20130683A1 (es) 2010-02-27 2013-06-20 Bayer Ip Gmbh Ariltriazolonas ligadas a bisarilo y su uso
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US9216978B2 (en) 2010-07-09 2015-12-22 Bayer Intellectual Property Gmbh Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2016071212A1 (en) 2014-11-03 2016-05-12 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof

Also Published As

Publication number Publication date
EP3452470B1 (en) 2020-03-18
TW201806943A (zh) 2018-03-01
US10815205B2 (en) 2020-10-27
US20190161454A1 (en) 2019-05-30
EP3452470A1 (en) 2019-03-13
AR108265A1 (es) 2018-08-01
UY37221A (es) 2017-11-30
WO2017191107A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
AR108263A1 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
CR20130102A (es) Imidazopiridazinas sustituidas
PH12016500169A1 (en) Polymorph of syk inhibitors
AR102487A1 (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
EP3424931A3 (en) Tetrahydronaphthalene derivatives that inhibit mcl-1 protein
TN2016000529A1 (en) Substituted dihydroisoquinolinone compounds
PH12018502497A1 (en) Adenosine derivatives for use in the treatment of cancer
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
CO7310531A2 (es) 4-metil-2,3,8,9,9b-pentaaza-ciclopenta [a] naftalenos
EA201791058A1 (ru) Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4)
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
MX2016015420A (es) Sales de dasatinib.
CR9684A (es) Nuevos derivados de la benzoheterocicliletil carboxamida
MX2017001459A (es) Sintesis de fosforamidatos.
MX2021006790A (es) Formulacion de tableta para compuestos activos de peptido relacionado con el gen de calcitonina.
MA37501B1 (fr) Composés de pyrazole utilisés en tant qu'inhibiteurs de sglt1
CR20180181A (es) Nuevos derivados de imidazol[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20190202A1 (es) Procedimiento para la preparacion de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
MX2019001393A (es) 1-hidroximetil-1,2,2,6-tetrametil-ciclohexano y sus derivados y su uso como productos quimicos aromaticos.
MX2019000138A (es) Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble.
MY161067A (en) Azabicycloalkane derivatives, preparation thereof and use thereof in therapy
CO2020008334A2 (es) Derivados de triptófano como endulzantes

Legal Events

Date Code Title Description
FB Suspension of granting procedure